Tarcan T, Ozveri H, Biren T, Türkeri L, Akdas A
Department of Urology, Marmara University School of Medicine, Istanbul, Turkey.
Int J Urol. 1997 Jul;4(4):362-7. doi: 10.1111/j.1442-2042.1997.tb00209.x.
This study was undertaken to assess the importance of prostate biopsies in patients with a negative digital rectal examination (DRE) and elevated prostate specific antigen (PSA) levels and to investigate the role of PSA density (PSAD) and hypoechoic lesions on transrectal ultrasound (TRUS) in increasing the diagnostic sensitivity and specificity for prostate cancer (PCa).
One hundred patients with varied initial symptoms who had a negative DRE and a PSA level between 4 and 20 ng/mL underwent TRUS-guided systematic and, if present, lesion-directed biopsies.
PCa was detected in 11 patients (11%). TRUS examinations revealed hypoechoic lesions in 31 patients. Lesion-directed biopsies revealed PCa in 13% (4/31) of patients with abnormal TRUS whereas, 7% (5/69) of patients with negative TRUS findings had PCa. Additional systematic biopsies detected PCa in 2 patients where lesion-directed biopsies were negative. None (0/19) of the lesions smaller than 0.2 mL on TRUS had PCa whereas, 33% (4/12) of patients with lesions greater than 0.2 mL had PCa. When the subgroup of patients with negative TRUS and PSA levels between 4 and 10 ng/mL were considered, 25% (1/4) of cases with PCa would have been missed if 0.15 was used as the cut-off point for PSAD, however, this would save 61% (30/49) of unnecessary biopsies. The positive predictive value of PSA (cut-off level 10 ng/mL), PSAD (cut-off level 0.15), and hypoechoic lesions on TRUS were found to be 11.5%, 33%, and 13%, respectively. When hypoechoic lesions greater than 0.2 mL were taken as the positive finding, the positive predictive value and specificity rates of TRUS increased to 33% and 91%, respectively, without any change in the sensitivity.
In patients with a negative DRE and intermediate PSA levels, the application of PSAD would have saved 49% of study patients with BPH from a biopsy, but would have missed 27% of PCa cases. By ignoring lesions smaller than 0.2 mL on TRUS, a very high specificity of 91% was achieved with a sensitivity of 36%. Thus, further investigations aimed at defining a better mode of diagnosis of PCa are warranted.
本研究旨在评估前列腺活检在直肠指检(DRE)阴性且前列腺特异性抗原(PSA)水平升高的患者中的重要性,并探讨PSA密度(PSAD)和经直肠超声(TRUS)上的低回声病变在提高前列腺癌(PCa)诊断敏感性和特异性方面的作用。
100例初始症状各异、DRE阴性且PSA水平在4至20 ng/mL之间的患者接受了TRUS引导下的系统活检,如有病变则进行靶向活检。
11例患者(11%)检测到PCa。TRUS检查发现31例患者有低回声病变。靶向活检在TRUS异常的患者中发现13%(4/31)患有PCa,而TRUS检查结果为阴性的患者中有7%(5/69)患有PCa。在靶向活检为阴性的2例患者中,额外的系统活检检测到PCa。TRUS上小于0.2 mL的病变均未发现PCa,而病变大于0.2 mL的患者中有33%(4/12)患有PCa。当考虑TRUS阴性且PSA水平在4至10 ng/mL之间的患者亚组时,如果将PSAD的截断点设为0.15,则会漏诊25%(1/4)的PCa病例,不过这将减少61%(30/49)不必要的活检。PSA(截断水平10 ng/mL)、PSAD(截断水平0.15)和TRUS上低回声病变的阳性预测值分别为11.5%、33%和13%。当将大于0.2 mL的低回声病变视为阳性发现时,TRUS的阳性预测值和特异性分别提高到33%和91%,而敏感性没有变化。
在DRE阴性且PSA水平中等的患者中,应用PSAD可使49%的良性前列腺增生(BPH)研究患者免于活检,但会漏诊27%的PCa病例。通过忽略TRUS上小于0.2 mL的病变,可实现91%的高特异性和36%的敏感性。因此,有必要进一步研究以确定更好的PCa诊断模式。